Gurgaon/ Tokyo,Feb.5 ANI | 2 years ago

The Board of Directors of Ranbaxy Laboratories Limited at its meeting held today, took on record the unaudited results for the Quarter and YTD ended December 31, 2013 under Indian GAAP.

Key Financial Highlights

Financial Performance for the quarter ended December 31, 2013 (Q4 FY14)

. Consolidated Sales were Rs.28.6 Bn [Q4'12: Sales Rs.26.7 Bn].

. Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs.2.7 Bn. Margins strengthened in the quarter. Adjusted for Forex movements and non-routine charges, margin was >10pc

The company recorded a net loss before taxes of Rs.0.6 Bn after providing for stock write-off and other costs of Rs.2.6 Bn pursuant to the inclusion of the Toansa plant under certain provisions of the Consent Decree (CD) by USFDA. (Please refer to the section "Regulatory, Research and Development and Manufacturing" for further details)

Financial Performance for YTD ended December 31, 2013 (YTD Dec'13)

. Consolidated sales were Rs.106.0 Bn [YTD Dec'12: Sales Rs.122.5 Bn]. Base business sales growth was led by India, East Europe and CIS and USA

. Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs.8.2 Bn. Base business margins improved over the corresponding period. Adjusted for Forex movements and non-routine charges, margin was > 10pc

Commenting on the business results for the quarter, Mr. Arun Sawhney, CEO and Managing Director, Ranbaxy, said, "Ranbaxy has been strengthening its base business in key markets including India, Eastern Europe and CIS and the USA which has helped us recover our margins. We are facing some major regulatory challenges and are disappointed with the developments. I would like to assure all our stakeholders that we will do whatever is necessary to address all concerns of the USFDA and are committed to resolve them as early as possible."

Key Highlights/ Developments


. Base business sales in Q4 FY14 continued to grow over the corresponding period

o Sales grew in the major markets of USA, India and East Europe

. Ranbaxy maintains strong market share in AbsoricaaEuro¢, isotretenoin NDA in the USA. As of December 27, 2013 Ranbaxy's market share was at 17.2pc . The Company had earlier in Sep 2013 received a Paragraph IV Certification Notice of filing from Watson Laboratories of an ANDA to the USFDA for a generic version of AbsoricaaEuro¢

Regulatory, Research and Development and Manufacturing

. The Toansa facility was issued a Form 483 containing certain observations in Jan 2014 and was subsequently included under certain provisions of the Consent Decree (CD) by USFDA. Subsequent to issuance of Form 483, the Company had voluntarily and proactively suspended shipments of API to the USA market from the facility out of abundant caution. Impact of the above-mentioned development was Rs.2.6 Bn on account of stock write-offs and other related costs that have been included below the EBITDA

. Remediation plan for Dewas and Paonta Sahib progresses in line with the Consent Decree

. Mohali plant was placed under the cGMP provisions of the CD in Sep 2013. All commitments to date have been met and remediation is progressing per plan

. Received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market SynriamaEuro¢ in India for the treatment of malaria caused by Plasmodium vivax parasite

. Received final approval from the USFDA to manufacture and market Felodipine Extended-Release tablets USP, 2.5 mg, 5 mg and 10 mg. Felodipine is indicated for the treatment of hypertension

. Received approval to market RanaEuro¢- Donepezil in Canada. Donepezil is indicated in the treatment of dementia in Alzheimer's patients

. The new entity established in Thailand started its operations during the quarter. Earlier in Jan 2013, Ranbaxy and Daiichi Sankyo had announced their intention to integrate their business operations in Thailand, to leverage and maximize the synergies under the Hybrid Business Model

. The Company completed 20 years of operations in Ukraine in Nov 2013

. Ranbaxy and EPIRUS announced signing of licensing agreement for BOW015, a biosimilar version of Infliximab used in the treatment of rheumatoid arthritis. The product will be introduced in India and other Emerging Markets. Currently, there is no biosimilar of Infliximab approved in India

. During the Quarter, 3 ANDAs were filed for the USA market

Global Sales

. Consolidated sales for the Quarter were Rs.28.6 Bn as compared to Rs.26.7 Bn, a growth of 7pc during the quarter. The details are as follows:

o Branded and OTC category contributed Rs.14.8 Bn accounting for 52pc of total sales during the Quarter. Generics including API category recorded Rs.13.8 Bn of sales for the Company during the Quarter

. North America: Sales for the Quarter were Rs.10.2 Bn

o In the USA sales for the Quarter were Rs.9.1 Bn

. India: In the domestic market, sales for the Quarter were Rs.5.8 Bn

o OTC business (Consumer Healthcare) contributed Rs.1.2 Bn

. East Europe and CIS: The region recorded sales of Rs.4.6 Bn

. West Europe: Sales for the Quarter were Rs.2.3 Bn

. Africa and Middle East: Sales for the Quarter were Rs.2.6 Bn

. Asia Pacific and LATAM (including Sri Lanka): Sales for the Quarter were Rs.1.7 Bn

. API business and others had revenues of Rs.1.4 Bn

(Posted on 06-02-2014)

Share This Page:

Free Yearly Horoscope: Select your zodiac sign

Pisces | Aquarius | Capricorn | Sagittarius | Scorpio | Libra | Virgo | Leo | Cancer | Gemini | Taurus | Aries